[go: up one dir, main page]

AR037791A1 - Compuestos derivados de benzotiofeno, su empleo, un procedimiento para prepararlos y medicamentos que los contienen - Google Patents

Compuestos derivados de benzotiofeno, su empleo, un procedimiento para prepararlos y medicamentos que los contienen

Info

Publication number
AR037791A1
AR037791A1 ARP020104799A ARP020104799A AR037791A1 AR 037791 A1 AR037791 A1 AR 037791A1 AR P020104799 A ARP020104799 A AR P020104799A AR P020104799 A ARP020104799 A AR P020104799A AR 037791 A1 AR037791 A1 AR 037791A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
compounds
receptor
pharmaceutically acceptable
useful
Prior art date
Application number
ARP020104799A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR037791A1 publication Critical patent/AR037791A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la fórmula general (1) en la cual: R es fenilo, opcionalmente sustituido por halógeno, o es piridin 3- ó 4-ilo, opcionalmente sustituido por alquilo inferior, o es -NR1R2, donde R1 y R2 forman conjuntamente con el átomo N al cual están unidos, anillos heterocíclicos seleccionados entre el grupo que comprenden morfolinilo, tiomorfolinilo, piperidinilo o piperazinilo, opcionalmente sustituido por -(CH2)n-hidroxi, alquilo inferior o alcoxi inferior; n es 0, 1 ó 2; y sales de adición de ácidos farmacéuticamente aceptables de los mismos, su empleo, un procedimiento para prepararlos y medicamentos que los contienen. Se ha demostrado que los compuestos de fórmula (1) y sus sales farmacéuticamente aceptables tienen buena afinidad por el receptor A2A y, por lo tanto, son útiles para el tratamiento de enfermedades relacionadas con este receptor, como ser la enfermedad de Alzheimer, enfermedad de Parkinson, neuroprotección, esquizofrenia, ansiedad, dolor, déficit respiratorio, depresión, asma, respuestas alérgicas, hipoxia, esquemia, convulsiones y abuso de sustancias. Además pueden ser útiles como sedantes, relajantes musculares, antipsicóticos, antiepilépticos, anticonvulsivantes y agentes cardioprotectores.
ARP020104799A 2001-12-12 2002-12-11 Compuestos derivados de benzotiofeno, su empleo, un procedimiento para prepararlos y medicamentos que los contienen AR037791A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01129269 2001-12-12

Publications (1)

Publication Number Publication Date
AR037791A1 true AR037791A1 (es) 2004-12-01

Family

ID=8179484

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104799A AR037791A1 (es) 2001-12-12 2002-12-11 Compuestos derivados de benzotiofeno, su empleo, un procedimiento para prepararlos y medicamentos que los contienen

Country Status (15)

Country Link
US (1) US6730670B2 (es)
EP (1) EP1456196B1 (es)
JP (1) JP4197649B2 (es)
KR (1) KR100581703B1 (es)
CN (1) CN1296368C (es)
AR (1) AR037791A1 (es)
AT (1) ATE420082T1 (es)
AU (1) AU2002358597C1 (es)
BR (1) BR0214936A (es)
CA (1) CA2469872A1 (es)
DE (1) DE60230808D1 (es)
MX (1) MXPA04005632A (es)
PL (1) PL370980A1 (es)
RU (1) RU2299882C2 (es)
WO (1) WO2003053954A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060058132A (ko) 2003-09-19 2006-05-29 에프. 호프만-라 로슈 아게 아데노신 수용체 리간드로서의 싸이아졸로피리딘 유도체
AU2006240248A1 (en) * 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
US5350748A (en) * 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
DE19749453A1 (de) * 1997-11-10 1999-05-12 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte anellierte 5-Ring-Verbindungen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
CA2344828A1 (en) * 1998-09-22 2000-03-30 Tomoyuki Kanda ¬1,2,4|triazolo¬1,5-c|pyrimidine derivatives
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives

Also Published As

Publication number Publication date
JP4197649B2 (ja) 2008-12-17
JP2006500313A (ja) 2006-01-05
US6730670B2 (en) 2004-05-04
DE60230808D1 (de) 2009-02-26
KR100581703B1 (ko) 2006-05-22
CN1602309A (zh) 2005-03-30
AU2002358597C1 (en) 2008-09-18
PL370980A1 (en) 2005-06-13
WO2003053954A1 (en) 2003-07-03
EP1456196A1 (en) 2004-09-15
RU2004121682A (ru) 2005-05-27
AU2002358597B2 (en) 2007-12-06
RU2299882C2 (ru) 2007-05-27
CA2469872A1 (en) 2003-07-03
ATE420082T1 (de) 2009-01-15
AU2002358597A1 (en) 2003-07-09
US20030149030A1 (en) 2003-08-07
CN1296368C (zh) 2007-01-24
MXPA04005632A (es) 2004-12-06
KR20040073477A (ko) 2004-08-19
BR0214936A (pt) 2004-12-14
EP1456196B1 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
SE0104334D0 (sv) Therapeutic agents
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
RU2003114748A (ru) Новые соединения, не являющиеся имидазолами
CN109641898A (zh) 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
HUP0401876A2 (hu) Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
BRPI0414266A (pt) derivados de tiazolopiridina como ligandos receptores da adenosina
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
AR036366A1 (es) Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
SE0400043D0 (sv) New compounds
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
JP2019537592A5 (es)
NZ528997A (en) Sulfonamides
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
MX2009005507A (es) Derivados de espiro-piperidina.
BR0214221A (pt) Derivados de benzotiazol como ligantes de receptores de adenosina
UY27593A1 (es) Nuevos compuestos
DK171133B1 (da) 1-Pyridyl- eller -pyrimidyl-4-substitueret alkyl-piperaziner eller -homopiperaziner, fremstilling af disse, samt farmaceutiske præparater indeholdende disse
ATE414090T1 (de) Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
FB Suspension of granting procedure